Keith Wilson
Faculty Member
Last active: 11/2/2019

Polypharmacy and Crohn's disease.

Cross RK, Wilson KT, Binion DG
Aliment Pharmacol Ther. 2005 21 (10): 1211-6

PMID: 15882241 · DOI:10.1111/j.1365-2036.2005.02429.x

BACKGROUND - Polypharmacy has not been defined for Crohn's disease.

AIMS - To determine the prevalence of polypharmacy, factors associated with polypharmacy, and consequences of polypharmacy in a Crohn's disease population.

METHODS - A review of 291 Crohn's disease patients was performed. Polypharmacy was defined as either minor (two to four medications) or major (> or = 5 medications). Clinical status was evaluated with the Harvey-Bradshaw index of disease activity (HBI) and the short inflammatory bowel disease questionnaire (SIBDQ).

RESULTS - Major polypharmacy was identified in 50% of patients. Crohn's disease patients on less than two medications at the intake visit had an HBI of 3.6 compared with 5.4 and 6.0 in the minor and major polypharmacy groups (P < 0.05). Similarly, patients on less than two medications had an SIBDQ of 60.3 compared with 55.7 and 53.4 in the minor and major polypharmacy groups (P = 0.11). Predictors of polypharmacy included age > 40 years (OR 1.9), duration of disease > 10 years (OR 2.0), and female sex (OR 2.5).

CONCLUSIONS - Polypharmacy is common in Crohn's disease and correlates with increased disease activity and decreased quality of life. Increasing age, increasing duration of disease, and female sex are associated with major polypharmacy. These findings emphasize the need for improved treatment algorithms to optimize Crohn's disease patient management.

MeSH Terms (15)

Adult Age Factors Aminosalicylic Acids Anti-Inflammatory Agents, Non-Steroidal Crohn Disease Female Humans Male Middle Aged Polypharmacy Quality of Life Retrospective Studies Risk Factors Severity of Illness Index Sex Factors

Connections (1)

This publication is referenced by other Labnodes entities:

Links